INTRODUCTION

Malignant pleural effusion (MPE) is a common symptom experienced by advanced stage cancer patients. This condition affects 500-700 individuals per million population and accounts for more than 125,000 hospital admissions every year in the United States.\textsuperscript{1,2} The estimated median survival for patients with MPE is 3-12 months.\textsuperscript{1} However, due to the development of local and systemic therapy, some recent studies have reported increased survival times.\textsuperscript{3,4} Although there has been notable progress in explaining the pathophysiology of MPE, challenges remain in diagnosis and precise prognostic assessment.\textsuperscript{5,6}

Thymidine kinase 1 concentration in pleural effusion is a diagnostic marker and survival predictor for malignant pleural effusion

Tian Tian\textsuperscript{1} | Jun Li\textsuperscript{2} | Wenjun Hu\textsuperscript{1} | Cuiling Sun\textsuperscript{1} | Jian Zhou\textsuperscript{1}

\textsuperscript{1}Department of Medical Oncology, Fuyang People's Hospital, Fuyang, China
\textsuperscript{2}Department of Medical Oncology, The First Affiliated Hospital of Anhui Medical University, Hefei, China

Correspondence
Tian Tian, Department of Medical Oncology, Fuyang People's Hospital, Fuyang, China. Email: tiannt@qq.com

Abstract

Objective: Thymidine kinase 1 (TK1) is a key enzyme in the pyrimidine salvage pathway. Increased TK1 concentration correlates with cell division. TK1 is an emerging biomarker in cancer diagnosis; however, its effectiveness in diagnosis and management for malignant pleural effusion (MPE) is unclear. We evaluated the diagnostic efficiency and prognostic value of pleural effusion TK1 (pTK1) concentration for MPE.

Methods: From 2013 to 2017, 210 pleural effusion samples were collected from 160 patients diagnosed with MPE and 50 patients diagnosed with benign pleural effusion (BPE). TK1 concentrations in pleural effusion were measured by chemiluminescence dot blot assays. The median follow-up was 12 months. We constructed a receiver-operating characteristic (ROC) curve to find the optimal cutoff value for MPE diagnosis. The hazard ratios were estimated using a multivariable Cox proportional hazard model. A nomogram was drawn to illustrate the prognostic characteristics of MPE.

Results: The TK1 concentration in pleural effusion was significantly higher in MPE than BPE (P < 0.001), and patients with MPE could be distinguished by an optimal cutoff value of 3.10 pmol/L with a sensitivity of 0.894 and a specificity of 0.800. The multivariate analysis suggested that pTK1 concentration was an independent predictor of survival in patients with MPE.

Conclusions: The diagnostic and prognostic prediction of MPE may be improved by measuring pTK1 concentration and utilizing a multivariate nomogram.

KEYWORDS
diagnosis, malignant pleural effusion, prognosis, Thymidine kinase 1
Thymidine kinase 1 (TK1) is an emerging biomarker in cancer diagnosis and outcome prediction. TK1 is a key enzyme in the pyrimidine salvage pathway and plays an important role in DNA precursor synthesis. The TK1 concentration increase in proliferating cells and studies have demonstrated that elevated expression of TK1 is associated with tumor cell division and proliferation. Serum TK1 (sTK1) is considered a marker to diagnose malignancy in the early stage, and a previous analysis also showed that serum TK1 is an independent predictor of tumor recurrence and is a prognostic factor for several types of cancer.

Biomarkers for the diagnosis and survival evaluation in pleural effusion have been extensively studied, and most soluble protein biomarkers are more effective when measured in pleural effusion than in serum. The use of pleural biomarkers offers a cost-effective and minimally invasive method for MPE management.

The primary aim of our study was to evaluate whether pTK1 can be used as a diagnostic biomarker for MPE. The secondary aim was to assess the prognostic value of pTK1 concentration in MPE. The third aim was to determine whether an effective nomogram could be created to predict MPE outcomes.

2 | METHODS

2.1 | Study population

A total of 210 patients who were diagnosed with pleural effusion for the first time and treated at the Fuyang People’s Hospital (Anhui, China) were included in this study. The selection criteria were as follows: (a) for benign pleural effusion (BPE) patients, the effusion was reduced or disappeared after receiving antibiotic therapy, and a one-year follow-up showed no relapse and no sign of malignant disease. (b) For MPE patients, primary cancer was confirmed by pathological diagnosis, and malignant cells were found in pleural effusion by cytology. The exclusion criteria were patients under 18 years old or with an expected survival of less than 1 month. The patients were followed up for a median of 1 year. Informed consent was obtained from each patient. The ethics research council of our hospital approved the protocol of this study.

2.2 | Clinical and biochemical measures

Performance status was assessed using the Eastern Cooperative Oncology Group Performance Status (ECOG PS) score. The pleural effusion samples were collected from the same pleural effusion sample sent for cytology examination. Each sample was stored at 4°C immediately after collection, and then, the TK1 concentration was measured in 24 h using a commercially available chemiluminescence dot blot assay kit (SSTK Biotech, Ltd., Shenzhen, China). Briefly, standards and effusion samples were directly transferred to a nitrocellulose membrane. Then, human anti-TK1 chicken immunoglobulin Y antibody was added to the samples. Next, the light intensities of spots were captured by an imaging system (SSTK Ltd., Shenzhen, China). Finally, curves were created to calculate the concentration.

2.3 | Statistical analysis

Normal distributed variables are shown as the mean and standard deviation. Categorical variables are expressed as absolute numbers with a percentage of subjects. Student’s t test was used to compare continuous variables. Skewed distribution data are presented as medians with the 25th and 75th percentile, and a nonparametric test (Mann-Whitney U) was conducted to evaluate differences in those data. Diagnostic accuracy was evaluated using a receiver-operating characteristics (ROC) curve. Overall survival (OS) was defined as the date of MPE diagnosis to the date of death or last contact. The optimal diagnosis cutoff was identified as the point with the maximum value of Youden index (sensitivity + specificity - 1). Univariate analysis was performed for potential cofounders. Variables that were significantly associated with survival were selected for multivariate Cox regression analysis applying the backward stepwise method, and hazard ratios (HRs) were estimated using this model. A nomogram was created to illustrate the outcome of the prognostic factors on OS. The concordance index (C-index) was calculated to assess the

FIGURE 1 PTK1 concentrations categorized by different patient groups
3 | RESULTS

3.1 | Patient characteristics

In total, 210 patients who met the criteria were included in our study. The MPE group included 160 patients. The diseases leading to MPE were lung cancer (143 patients), breast cancer (five patients), esophageal cancer (five patients), gastric cancer (five patients), and mesothelioma (two patients). The BPE group consisted of 50 patients (parapneumonic effusion, 29 patients; tuberculous pleural effusion, 21 patients). Among the 160 patients with MPE, 73 were male and 87 were female, with a mean age of 59.7 ± 9.12. Regarding 50 patients with BPE, 23 were male and 27 were female, with a mean age of 57.3 ± 9.98.

3.2 | Accuracy of pTK1 concentrations to diagnose MPE

The concentration of pTK1 in cases of MPE was 5.01 (3.55-7.63) pmol/L, while in cases of BPE, it was 2.44 (1.81-3.05) pmol/L. The median value of pTK1 in MPE was significantly higher than that in BPE (P < 0.001, Figure 1. The ROC curve of pTK1 in MPE patients was plotted, and the AUC was 0.881 (95% confidence interval [CI]: 0.826-0.937, P < 0.001, Figure 2). PTK1 revealed the highest sensitivity (0.894) and specificity (0.800), with an optimal cutoff value of 3.10 pmol/L.

3.3 | PTK1 concentrations and prognosis

Age, gender, smoking, ECOG PS, pathological type, smoking history, multiple metastasis, pTK1, sTK1, T stage, and N stage of primary cancer were regarded as potential cofounders, and Kaplan-Meier
univariate survival analysis was performed. Patients with elevated pTK1 had a significantly decreased OS. The median values for OS of patients with high pTK1 values and with low pTK1 values were 8.4 and 12.2 months, respectively Figure 3. Pathological type other than adenocarcinoma, multiple metastasis, and poor PS score were also associated with significantly decreased OS Table 1.

### TABLE 1

Clinicopathological characteristics of patients with MPE and the associated median survival time

| Characteristic                                           | Cases, n (%) | median survival time | $\chi^2$ | $P$  |
|----------------------------------------------------------|--------------|----------------------|----------|------|
| Age, years                                               |              |                      |          |      |
| <60                                                      | 77           | 335                  | 0.544    | 0.461|
| ≥60                                                      | 83           | 365                  |          |      |
| Gender                                                   |              |                      |          |      |
| Male                                                     | 73           | 331                  | 0.162    | 0.687|
| Female                                                   | 87           | 351                  |          |      |
| ECOG performance status score                            |              |                      |          |      |
| ≤2                                                       | 69           | 425                  | 114.381  | <0.001|
| >2                                                       | 91           | 291                  |          |      |
| Pathological type                                         |              |                      |          |      |
| Adenocarcinoma                                           | 129          | 365                  | 22.661   | <0.001|
| Other pathological types                                 | 31           | 253                  |          |      |
| Smoking history                                          |              |                      |          |      |
| Yes                                                      | 41           | 341                  | 0.001    | 0.970|
| No                                                       | 119          | 340                  |          |      |
| Multiple metastasis                                      |              |                      |          |      |
| Yes                                                      | 42           | 335                  | 21.894   | <0.001|
| No                                                       | 118          | 410                  |          |      |
| Time interval between MPE and primary cancer diagnosis   |              |                      |          |      |
| <60                                                      | 66           | 321                  | 4.706    | 0.030|
| ≥60                                                      | 94           | 354                  |          |      |
| Serum TK1 level                                          |              |                      |          |      |
| <2.00 pmol/L                                             | 71           | 356                  | 0.817    | 0.366|
| ≥2.00 pmol/L                                             | 89           | 329                  |          |      |
| Pleural effusion TK1 level                               |              |                      |          |      |
| <6.90 pmol/L                                             | 111          | 365                  | 36.111   | <0.001|
| ≥6.90 pmol/L                                             | 49           | 253                  |          |      |
| N stage of primary cancer                                |              |                      |          |      |
| ≤2                                                       | 79           | 345                  | 0.600    | 0.439|
| >2                                                       | 81           | 336                  |          |      |
| T stage of primary cancer                                |              |                      |          |      |
| ≤2                                                       | 80           | 350                  | 0.064    | 0.800|
| >2                                                       | 80           | 358                  |          |      |

### TABLE 2

Cox regression analysis of factors affecting patient prognosis

| Characteristic                        | Regression coefficient | Standard error | Wald  | HR   | 95% CI        | $P$  |
|---------------------------------------|------------------------|----------------|-------|------|---------------|------|
| Pathological type                     | -0.957                 | 0.225          | 18.181| 0.384| 0.247-0.596   | <0.001|
| ECOG PS                               | -1.968                 | 0.216          | 82.737| 0.140| 0.091-0.214   | <0.001|
| Pleural TK1 level                     | -0.871                 | 0.196          | 19.857| 0.418| 0.285-0.614   | <0.001|
| Multiple metastasis                   | -0.700                 | 0.208          | 11.343| 0.496| 0.330-0.746   | 0.001|

CI, confidence interval; HR, hazard ratio.
3.4 Development and validation of the survival model

Multivariate backward stepwise Cox regression analysis was conducted to identify independent factors from statistically significant variables ($P < 0.05$) proven by Kaplan-Meier univariate analysis Table 2. This Cox model was then used to create a nomogram Figure 4. The C-index for 1-year OS prediction was up to 0.817 (95% CI: 0.792-0.842), and the calibration plot for the probability of 1-year survival exhibited an ideal agreement between nomogram-predicted probability and actual survival Figure 5.

4 DISCUSSION

Although the gold standard of MPE diagnosis is cytopathology, occasionally, several sampling times were required for identification of malignant cancer cells with microscopy. Various markers have been suggested as noninvasive tests to help discriminate between BPE and MPE and to provide prognostic information. The most heavily studied diagnostic biomarker in pleural effusion is carcinoembryonic antigen (CEA). A meta-analysis including 49 studies suggested that the pooled sensitivity and specificity of pleural effusion CEA for diagnosing MPE were 0.549 and 0.962. In a previous study, the diagnostic value of TK, neuron-specific enolase (NSE), CEA, and cytokeratin fragment 19 (CYFRA 21-1) was determined, and the TK concentration was investigated using a radio enzyme assay. The TK concentration had the highest diagnostic accuracy (Youden index: 0.85) among the above markers. In our study, using a cutoff point of 3.10 pmol/L, the sensitivity and specificity of pTK1 for detecting MPE were 0.894 and 0.800, respectively. The LENT score system was calculated by four variables, including pleural fluid lactate dehydrogenase (LDH) level, ECOG PS, neutrophil-to-lymphocyte ratio.

![Nomogram for predicting 1-year overall survival rates in patients with MPE](image)

![Calibration plot of the nomogram for the probability of 1-year survival](image)
(NLR), and tumor type, and it is widely used in risk stratification of MPE patients. However, a recent study suggested that it underestimates the prognosis in patients with MPE caused by lung adenocarcinoma. The recently published PROMISE score system includes a clinical score method and a biological score method, which is a clinical score plus tissue inhibitor of metalloproteinases 1 (TIMP1). However, this system can only predict the 3-month mortality, and adding TIMP1 to the score system only contributed very modest effects, which limited its clinical value. In our study, pTK1 was proven to be significant in the univariate test, and multivariate Cox regression analysis demonstrated that pTK1 is an independent prognostic factor, contributing to a strong effect in the survival model.

TK exists in two forms: TK1 is found primarily in the cytoplasm, and TK2 is concentrated in mitochondria. Since TK1 is cell-cycle regulated and TK2 is constitutively expressed, the value of sTK1 as a biomarker for diagnosis and its prognostic significance in lung cancer, breast cancer, esophageal cancer, and gastric cancer have been investigated in recent years, and our study analyzed the TK1 concentration in pleural effusion for the first time.

Nomograms have been created to assess survival factors in various malignancies. Nomograms are useful for visualizing prognostic factors and may help physicians make precise and individualized predictions of MPE outcomes. However, to the best of our knowledge, a nomogram to predict the probability of 1-year survival for MPE patients has not been reported.

There are both strengths and limitations in our study. A major limitation of our study was that the sample size was relatively small and performed in a single institution. Another limitation is the lack of external validation for our survival model. Multicenter studies are required to validate the diagnostic and prognostic precision of this model.

5 | CONCLUSION

We evaluated the value of measuring pTK1 concentration in the diagnostic and prognostic prediction of MPE and established a nomogram for predicting 1-year survival. As pTK1 measurement is noninvasive and shows high diagnostic and prognostic value, it may be a useful biomarker in MPE management.

ACKNOWLEDGMENTS

Financial support was provided by the hospital funds.

CONFLICT OF INTEREST

The authors declare no conflict of interest.

ORCID

Tian Tian https://orcid.org/0000-0001-5997-8925

REFERENCES

1. Roberts ME, Neville E, Berrisford RG, Antunes G, Ali NJ. Management of a malignant pleural effusion: British Thoracic Society Pleural Disease Guideline 2010. Thorax. 2010;65(Suppl 2):ii32–ii40.
2. Feller-Kopman DJ, Reddy CB, DeCamp MM, et al. Management of malignant pleural effusions. An official ATS/STS/STR Clinical Practice Guideline. Am J Respir Crit Care Med. 2018;198(7):839–849.
3. Nam H-S. Malignant pleural effusion: medical approaches for diagnosis and management. Tuberc Respir Dis. 2014;76(5):211–217.
4. Fitzgerald DB, Koegelenberg CF, Yasufuku K, Lee YG. Surgical and non-surgical management of malignant pleural effusions. Expert Rev Respir Med. 2018;12(1):15–26.
5. Psalidas I, Kolomenidis I, Porcel JM, Robinson BW, Stathopoulos GT. Malignant pleural effusion: from bench to bedside. Eur Respir Rev. 2016;25(140):189–198.
6. McCracken DJ, Porcel JM, Rahman NM. Malignant pleural effusions: management options. Semin Respir Crit Care Med. 2018;39(6):704–712.
7. Auferklamm S, Todenhöfer T, Gakis G, et al. Thymidine kinase and cancer monitoring. Cancer Lett. 2012;316(1):6–10.
8. Jagarlamudi KK, Shaw M. Thymidine kinase 1 as a tumor biomarker: technical advances offering new potential to an old biomarker. Biomark Med. 2018;12(9):1035–1048.
9. Von Euler H, Eriksson S. Comparative aspects of the proliferation marker thymidine kinase 1 in human and canine tumour diseases. Vet Comp Oncol. 2011;9(1):1–15.
10. Wang Yu, Jiang X, Wang S, et al. Serological TK1 predict pre-cancer in routine health screenings of 56,178 people. Cancer Biomarkers. 2018;22(2):237–247.
11. Zhou J, He E, Skog S. The proliferation marker thymidine kinase 1 in clinical use. Mol Clin Oncol. 2013;3(1):18–28.
12. Porcel JM. Pleural fluid biomarkers: beyond the Light criteria. Clin Chest Med. 2013;34(1):27–37.
13. Porcel JM. Biomarkers in the diagnosis of pleural diseases: a 2018 update. Ther Adv Respir Dis. 2018;12:1753466618808660.
14. Nguyen AH, Miller EJ, Wichman CS, Berim IG, Agrawal DK. Diagnostic value of tumor antigens in malignant pleural effusion: a meta-analysis. Transf Res. 2015;166(5):432–439.
15. Dietrich D, Jung M, Puetszer S, et al. Diagnostic and prognostic value of SHOX2 and SEPT9 DNA methylation and cytology in benign, paramalignant and malignant pleural effusions. PLoS ONE. 2013;8(12):e84225.
16. Zhang F, Hu L, Wang J, Chen J, Chen J, Wang Y. Clinical value of jointly detection serum lactate dehydrogenase/pleural fluid adenosine deaminase and pleural fluid carcinoembryonic antigen in the identification of malignant pleural effusion. J Clin Lab Anal. 2017;31(5):e22106.
17. Walker S, Bibby AC, Maskell NA. Current best practice in the evaluation and management of malignant pleural effusions. Ther Adv Respir Dis. 2017;11(2):105–114.
18. Topolcan O, Holubec L, Polivkova V, et al. Tumor markers in pleural effusions. Anticancer Res. 2007;27(4a):1921–1924.
19. Clive AO, Kahan BC, Hooper CE, et al. Predicting survival in malignant pleural effusion: development and validation of the LENT prognostic score. Thorax. 2014;69(12):1098–1104.
20. Abisheganaden J, Verma A, Dagaonkar RS, Light RW. An observational study evaluating the performance of LENT score in the selected population of malignant pleural effusion from lung adenocarcinoma in Singapore. Respiration. 2018;96(4):308–313.
21. Psalidas I, Kanellakis NI, Gerry S, et al. Development and validation of response markers to predict survival and pleurodesis success in patients with malignant pleural effusion (PROMISE): a multicohort analysis. Lancet Oncol. 2018;19(7):930–939.
22. Baas P, Burgers S. Malignant pleural effusions: will PROMISE make its name true? Lancet Oncol. 2018;19(7):853–855.
23. Munch-Petersen B, Cloos L, Jensen HK, Tyrsted G. Human thymidine kinase 1. Regulation in normal and malignant cells. Adv Enzyme Regul. 1995;35:69–89.
24. He E, Xu X, Guan H, et al. Thymidine kinase 1 is a potential marker for prognosis and monitoring the response to treatment of patients with breast, lung, and esophageal cancer and non-Hodgkin’s lymphoma. Nucleosides, Nucleotides Nucleic Acids. 2010;29(4–6):352–358.
25. Li H, Lei D, Wang X, Skog S, He Q. Serum thymidine kinase 1 is a prognostic and monitoring factor in patients with non-small cell lung cancer. Oncol Rep. 2005;13(1):145–149.
26. Holdenrieder S, Von Pawel J, Duell T, et al. Clinical relevance of Thymidine Kinase for the diagnosis, therapy monitoring and prognosis of non-operable lung cancer. Anticancer Res. 2010;30(5):1855–1862.
27. Balachandran VP, Gonen M, Smith JJ, DeMatteo RP. Nomograms in oncology: more than meets the eye. Lancet Oncol. 2015;16(4):e173–e180.

How to cite this article: Tian T, Li J, Hu W, Sun C, Zhou J. Thymidine kinase 1 concentration in pleural effusion is a diagnostic marker and survival predictor for malignant pleural effusion. J Clin Lab Anal. 2019;33:e22901. https://doi.org/10.1002/jcla.22901